These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 15844618

  • 1. Small interfering RNA for experimental cancer therapy.
    Tong AW, Zhang YA, Nemunaitis J.
    Curr Opin Mol Ther; 2005 Apr; 7(2):114-24. PubMed ID: 15844618
    [Abstract] [Full Text] [Related]

  • 2. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
    Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW.
    Cancer Res; 2006 Oct 01; 66(19):9736-43. PubMed ID: 17018633
    [Abstract] [Full Text] [Related]

  • 3. Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC.
    Pan Q, Liu B, Liu J, Cai R, Liu X, Qian C.
    Acta Oncol; 2008 Oct 01; 47(1):135-44. PubMed ID: 17934893
    [Abstract] [Full Text] [Related]

  • 4. Use of adeno-associated viral vector for delivery of small interfering RNA.
    Tomar RS, Matta H, Chaudhary PM.
    Oncogene; 2003 Aug 28; 22(36):5712-5. PubMed ID: 12944921
    [Abstract] [Full Text] [Related]

  • 5. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A.
    J Biotechnol; 2006 Jun 25; 124(1):12-25. PubMed ID: 16413079
    [Abstract] [Full Text] [Related]

  • 6. RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics.
    de Fougerolles A, Manoharan M, Meyers R, Vornlocher HP.
    Methods Enzymol; 2005 Jun 25; 392():278-96. PubMed ID: 15644187
    [Abstract] [Full Text] [Related]

  • 7. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
    Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D, Kalvakolanu DV, Kopecko DJ, Zhao X, Xu DQ.
    Clin Cancer Res; 2005 Sep 01; 11(17):6333-41. PubMed ID: 16144938
    [Abstract] [Full Text] [Related]

  • 8. siRNA delivery systems for cancer treatment.
    Oh YK, Park TG.
    Adv Drug Deliv Rev; 2009 Aug 10; 61(10):850-62. PubMed ID: 19422869
    [Abstract] [Full Text] [Related]

  • 9. Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA.
    Sabbioni S, Callegari E, Manservigi M, Argnani R, Corallini A, Negrini M, Manservigi R.
    Gene Ther; 2007 Mar 10; 14(5):459-64. PubMed ID: 17051250
    [Abstract] [Full Text] [Related]

  • 10. Retroviral delivery of small interfering RNA into primary cells.
    Barton GM, Medzhitov R.
    Proc Natl Acad Sci U S A; 2002 Nov 12; 99(23):14943-5. PubMed ID: 12417750
    [Abstract] [Full Text] [Related]

  • 11. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S, Benter I.
    Adv Drug Deliv Rev; 2007 Mar 30; 59(2-3):164-82. PubMed ID: 17481774
    [Abstract] [Full Text] [Related]

  • 12. siRNA-based approaches in cancer therapy.
    Devi GR.
    Cancer Gene Ther; 2006 Sep 30; 13(9):819-29. PubMed ID: 16424918
    [Abstract] [Full Text] [Related]

  • 13. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
    Sun Y, Li Z, Li L, Li J, Liu X, Li W.
    Int J Mol Med; 2007 Apr 30; 19(4):705-11. PubMed ID: 17334648
    [Abstract] [Full Text] [Related]

  • 14. Selection and validation of optimal siRNA target sites for RNAi-mediated gene silencing.
    Luo Q, Kang Q, Song WX, Luu HH, Luo X, An N, Luo J, Deng ZL, Jiang W, Yin H, Chen J, Sharff KA, Tang N, Bennett E, Haydon RC, He TC.
    Gene; 2007 Jun 15; 395(1-2):160-9. PubMed ID: 17449199
    [Abstract] [Full Text] [Related]

  • 15. Management of chronic hepatitis B virus infection: a promising approach using small interfering RNA (siRNA).
    Dwivedi M, Misra SP, Misra V, Waikhom RK, Bhatnagar M.
    Natl Med J India; 2008 Jun 15; 21(3):123-7. PubMed ID: 19004143
    [Abstract] [Full Text] [Related]

  • 16. siRNA therapeutics: big potential from small RNAs.
    Ryther RC, Flynt AS, Phillips JA, Patton JG.
    Gene Ther; 2005 Jan 15; 12(1):5-11. PubMed ID: 15496962
    [Abstract] [Full Text] [Related]

  • 17. Novel siRNA-based molecular beacons for dual imaging and therapy.
    Chang E, Zhu MQ, Drezek R.
    Biotechnol J; 2007 Apr 15; 2(4):422-5. PubMed ID: 17330221
    [Abstract] [Full Text] [Related]

  • 18. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A.
    Curr Opin Mol Ther; 2007 Aug 15; 9(4):345-52. PubMed ID: 17694447
    [Abstract] [Full Text] [Related]

  • 19. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing.
    Bartlett DW, Davis ME.
    Biotechnol Bioeng; 2007 Jul 01; 97(4):909-21. PubMed ID: 17154307
    [Abstract] [Full Text] [Related]

  • 20. The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence.
    Fluiter K, Mook OR, Baas F.
    Methods Mol Biol; 2009 Jul 01; 487():189-203. PubMed ID: 19301648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.